Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Power estimations for non-primary outcomes in randomised clinical trials.

Jakobsen JC, Ovesen C, Winkel P, Hilden J, Gluud C, Wetterslev J.

BMJ Open. 2019 Jun 6;9(6):e027092. doi: 10.1136/bmjopen-2018-027092.

2.

Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study.

Ruge T, Carlsson AC, Kjøller E, Hilden J, Kolmos HJ, Sajadieh A, Kastrup J, Jensen GB, Larsson A, Nowak C, Jakobsen JC, Winkel P, Gluud C, Ärnlöv J.

Atherosclerosis. 2019 May;284:202-208. doi: 10.1016/j.atherosclerosis.2019.02.031. Epub 2019 Mar 3.

PMID:
30959314
3.

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.

Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP.

Haematologica. 2019 May;104(5):986-992. doi: 10.3324/haematol.2018.204545. Epub 2018 Dec 13.

4.

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA.

Oncogene. 2019 Mar;38(13):2241-2262. doi: 10.1038/s41388-018-0567-7. Epub 2018 Nov 26.

5.

Reproducibility of the Measurement of Bulk/Tapped Density of Pharmaceutical Powders Between Pharmaceutical Laboratories.

Akseli I, Hilden J, Katz JM, Kelly RC, Kramer TT, Mao C, Osei-Yeboah F, Strong JC.

J Pharm Sci. 2019 Mar;108(3):1081-1084. doi: 10.1016/j.xphs.2018.10.009. Epub 2018 Oct 13.

PMID:
30326209
6.

Dropwise Additive Manufacturing of Pharmaceutical Products Using Particle Suspensions.

Radcliffe AJ, Hilden JL, Nagy ZK, Reklaitis GV.

J Pharm Sci. 2019 Feb;108(2):914-928. doi: 10.1016/j.xphs.2018.09.030. Epub 2018 Oct 9.

PMID:
30308177
7.

Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study.

Wuopio J, Hilden J, Bring C, Kastrup J, Sajadieh A, Jensen GB, Kjøller E, Kolmos HJ, Larsson A, Jakobsen JC, Winkel P, Gluud C, Carlsson AC, Ärnlöv J.

Atherosclerosis. 2018 Nov;278:97-102. doi: 10.1016/j.atherosclerosis.2018.09.006. Epub 2018 Sep 15.

PMID:
30261474
8.

Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course.

Winkel P, Jakobsen JC, Hilden J, Jensen G, Kjøller E, Sajadieh A, Kastrup J, Kolmos HJ, Larsson A, Ärnlöv J, Gluud C.

Open Heart. 2018 Sep 5;5(2):e000808. doi: 10.1136/openhrt-2018-000808. eCollection 2018.

9.

Tablet Compression Force as a Process Analytical Technology (PAT): 100% Inspection and Control of Tablet Weight Uniformity.

Manley L, Hilden J, Valero P, Kramer T.

J Pharm Sci. 2019 Jan;108(1):485-493. doi: 10.1016/j.xphs.2018.07.004. Epub 2018 Sep 6.

PMID:
30009799
10.

Assessment of Intragranular and Extragranular Fracture in the Development of Tablet Tensile Strength.

Mitra B, Hilden J, Litster J.

J Pharm Sci. 2018 Oct;107(10):2581-2591. doi: 10.1016/j.xphs.2018.05.011. Epub 2018 May 24.

11.

Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies.

Olsen MF, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A.

J Clin Epidemiol. 2018 Sep;101:87-106.e2. doi: 10.1016/j.jclinepi.2018.05.007. Epub 2018 May 21. Review.

PMID:
29793007
12.

Correction: Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.

Nycz BT, Dominguez SR, Friedman D, Hilden JM, Ir D, Robertson CE, Frank DN.

PLoS One. 2018 May 10;13(5):e0197530. doi: 10.1371/journal.pone.0197530. eCollection 2018.

13.

10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial Substudy.

Carlsson AC, Ruge T, Kjøller E, Hilden J, Kolmos HJ, Sajadieh A, Kastrup J, Jensen GB, Larsson A, Nowak C, Jakobsen JC, Winkel P, Gluud C, Ärnlöv J.

J Am Heart Assoc. 2018 Apr 23;7(9). pii: e008299. doi: 10.1161/JAHA.117.008299.

14.

Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.

Nycz BT, Dominguez SR, Friedman D, Hilden JM, Ir D, Robertson CE, Frank DN.

PLoS One. 2018 Jan 12;13(1):e0191232. doi: 10.1371/journal.pone.0191232. eCollection 2018. Erratum in: PLoS One. 2018 May 10;13(5):e0197530.

15.

Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.

Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.

16.

The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2-Implications for fellowship training.

Leavey PJ, Hilden JM, Matthews D, Dandoy C, Badawy SM, Shah M, Wayne AS, Hord J; American Society of Pediatric Hematology/Oncology Workforce Advisory Taskforce.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26765. Epub 2017 Oct 25.

PMID:
29068565
17.

The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce.

Hord J, Shah M, Badawy SM, Matthews D, Hilden J, Wayne AS, Salsberg E, Leavey PS; American Society of Pediatric Hematology/Oncology Workforce Advisory Taskforce.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26780. Epub 2017 Oct 25.

PMID:
29068564
18.

Improved sensitivity and specificity of pediatric hospital-acquired venous thromboembolism case identification by addition of radiographic and pharmacologic elements.

Dittmar M, Smith N, Warren B, Clark B, Wathen B, Hammett K, Reiter P, Hilden J, Goldenberg N, Branchford B.

Thromb Res. 2017 Jun;154:93-95. doi: 10.1016/j.thromres.2017.04.017. Epub 2017 Apr 17. No abstract available.

PMID:
28456027
19.

Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial.

Winkel P, Jakobsen JC, Hilden J, Lange T, Jensen GB, Kjøller E, Sajadieh A, Kastrup J, Kolmos HJ, Larsson A, Ärnlöv J, Gluud C.

Diagn Progn Res. 2017 Mar 29;1:10. doi: 10.1186/s41512-017-0009-y. eCollection 2017.

20.

Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain.

Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A.

BMC Med. 2017 Feb 20;15(1):35. doi: 10.1186/s12916-016-0775-3. Review.

21.

Note on the Use of Diametrical Compression to Determine Tablet Tensile Strength.

Hilden J, Polizzi M, Zettler A.

J Pharm Sci. 2017 Jan;106(1):418-421. doi: 10.1016/j.xphs.2016.08.004. Epub 2016 Sep 26.

PMID:
27686682
22.

Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report.

Rogers AE, Eisenman KM, Dolan SA, Belderson KM, Zauche JR, Tong S, Gralla J, Hilden JM, Wang M, Maloney KW, Dominguez SR.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26254. Epub 2016 Sep 12.

PMID:
27616655
23.

Early career mentoring through the American Society of Pediatric Hematology/Oncology: Lessons learned from a pilot program.

Badawy SM, Black V, Meier ER, Myers KC, Pinkney K, Hastings C, Hilden JM, Zweidler-McKay P, Stork LC, Johnson TS, Vaiselbuh SR.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26252. Epub 2016 Sep 12.

24.

Navigating your career path in pediatric hematology/oncology: On and off the beaten track.

Zweidler-McKay PA, Hogan MJ, Jubran R, Black V, Casillas J, Harper J, Malempati S, Margolin J, Felgenhauer J, Sakamoto KM, Franklin J, Shah M, Seibel N, Buchanan G, Vaiselbuh SR, Hastings C, Hilden J, Stork LC.

Pediatr Blood Cancer. 2016 Oct;63(10):1723-30. doi: 10.1002/pbc.26094. Epub 2016 Jun 13. No abstract available.

PMID:
27295503
25.

Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) Guidelines, V.2.0: examples of SQUIRE elements in the healthcare improvement literature.

Goodman D, Ogrinc G, Davies L, Baker GR, Barnsteiner J, Foster TC, Gali K, Hilden J, Horwitz L, Kaplan HC, Leis J, Matulis JC, Michie S, Miltner R, Neily J, Nelson WA, Niedner M, Oliver B, Rutman L, Thomson R, Thor J.

BMJ Qual Saf. 2016 Dec;25(12):e7. doi: 10.1136/bmjqs-2015-004480. Epub 2016 Apr 13.

26.

Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?

Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J.

Clin Chem. 2016 May;62(5):737-42. doi: 10.1373/clinchem.2015.252163. Epub 2016 Mar 21.

27.

The matching quality of experimental and control interventions in blinded pharmacological randomised clinical trials: a methodological systematic review.

Bello S, Wei M, Hilden J, Hróbjartsson A.

BMC Med Res Methodol. 2016 Feb 13;16:18. doi: 10.1186/s12874-016-0111-9. Review.

28.

It is Time to Let in Pediatric Palliative Care.

Hilden J.

Pediatr Blood Cancer. 2016 Apr;63(4):583-4. doi: 10.1002/pbc.25877. Epub 2016 Jan 21. No abstract available.

PMID:
26797913
29.

Investigation of a cluster of Clostridium difficile infections in a pediatric oncology setting.

Dantes R, Epson EE, Dominguez SR, Dolan S, Wang F, Hurst A, Parker SK, Johnston H, West K, Anderson L, Rasheed JK, Moulton-Meissner H, Noble-Wang J, Limbago B, Dowell E, Hilden JM, Guh A, Pollack LA, Gould CV.

Am J Infect Control. 2016 Feb;44(2):138-45. doi: 10.1016/j.ajic.2015.09.004. Epub 2015 Oct 23.

PMID:
26601705
30.

The Net Reclassification Index (NRI): a Misleading Measure of Prediction Improvement Even with Independent Test Data Sets.

Pepe MS, Fan J, Feng Z, Gerds T, Hilden J.

Stat Biosci. 2015 Oct 1;7(2):282-295. Epub 2014 Aug 23.

31.

Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group.

Cohen BH, Geyer JR, Miller DC, Curran JG, Zhou T, Holmes E, Ingles SA, Dunkel IJ, Hilden J, Packer RJ, Pollack IF, Gajjar A, Finlay JL; Children's Oncology Group.

Pediatr Neurol. 2015 Jul;53(1):31-46. doi: 10.1016/j.pediatrneurol.2015.03.019. Epub 2015 Apr 9.

32.

A multidisciplinary approach to the management of anterior mediastinal masses in children.

Acker SN, Linton J, Tan GM, Garrington TP, Bruny J, Hilden JM, Hoffman LM, Partrick DA.

J Pediatr Surg. 2015 May;50(5):875-8. doi: 10.1016/j.jpedsurg.2014.09.054. Epub 2014 Oct 3.

PMID:
25783332
33.

Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs.

Salstrom JL, Coughlin RL, Pool K, Bojan M, Mediavilla C, Schwent W, Rannie M, Law D, Finnerty M, Hilden J.

Pediatr Blood Cancer. 2015 May;62(5):807-15. doi: 10.1002/pbc.25435. Epub 2015 Feb 7.

34.

Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.

Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ, Kjøller E, Jensen GB, Skoog M, Lindschou J, Gluud C; CLARICOR trial group.

Int J Cardiol. 2015 Mar 1;182:459-65. doi: 10.1016/j.ijcard.2015.01.020. Epub 2015 Jan 6.

PMID:
25602299
35.

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P.

Pediatr Blood Cancer. 2015 Mar;62(3):414-8. doi: 10.1002/pbc.25311. Epub 2014 Nov 18.

36.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

37.

Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial.

Kjøller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, Fischer Hansen J, Kastrup J, Jespersen CM, Hildebrandt P, Kolmos HJ, Gluud C; CLARICOR Trial Group.

Am Heart J. 2014 Aug;168(2):197-204.e1-4. doi: 10.1016/j.ahj.2013.12.032. Epub 2014 May 4.

PMID:
25066559
38.

Calibration of models is not sufficient to justify NRI.

Gerds TA, Hilden J.

Stat Med. 2014 Aug 30;33(19):3419-20. doi: 10.1002/sim.6212. No abstract available.

PMID:
25042216
39.

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial.

Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, Jensen GB, Kjøller E, Winkel P, Flyvbjerg A, Gluud C; Claricor Trial Group.

Scand J Clin Lab Invest. 2014 Nov;74(8):657-64. doi: 10.3109/00365513.2014.930510. Epub 2014 Jul 15.

PMID:
25026506
40.

Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies.

Hróbjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S.

Int J Epidemiol. 2014 Aug;43(4):1272-83. doi: 10.1093/ije/dyu115. Epub 2014 May 30. Review.

41.

High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients.

Dominguez SR, Dolan SA, West K, Dantes RB, Epson E, Friedman D, Littlehorn CA, Arms LE, Walton K, Servetar E, Frank DN, Kotter CV, Dowell E, Gould CV, Hilden JM, Todd JK.

Clin Infect Dis. 2014 Aug 1;59(3):401-3. doi: 10.1093/cid/ciu302. Epub 2014 Apr 29.

PMID:
24785235
42.

Commentary: On NRI, IDI, and "good-looking" statistics with nothing underneath.

Hilden J.

Epidemiology. 2014 Mar;25(2):265-7. doi: 10.1097/EDE.0000000000000063. No abstract available.

PMID:
24487208
43.

Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors.

Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Rasmussen JV, Hilden J, Boutron I, Ravaud P, Brorson S.

Int J Epidemiol. 2014 Jun;43(3):937-48. doi: 10.1093/ije/dyt270. Epub 2014 Jan 21. Review.

PMID:
24448109
44.

Excess congenital non-synonymous variation in leukemia-associated genes in MLL- infant leukemia: a Children's Oncology Group report.

Valentine MC, Linabery AM, Chasnoff S, Hughes AE, Mallaney C, Sanchez N, Giacalone J, Heerema NA, Hilden JM, Spector LG, Ross JA, Druley TE.

Leukemia. 2014 Jun;28(6):1235-41. doi: 10.1038/leu.2013.367. Epub 2013 Dec 4.

45.

Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.

Lyngbæk S, Winkel P, Gøtze JP, Kastrup J, Gluud C, Kolmos HJ, Kjøller E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J; CLARICOR Trial Group.

Eur J Prev Cardiol. 2014 Oct;21(10):1275-84. doi: 10.1177/2047487313492099. Epub 2013 May 30.

PMID:
23723326
46.

A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index.

Hilden J, Gerds TA.

Stat Med. 2014 Aug 30;33(19):3405-14. doi: 10.1002/sim.5804. Epub 2013 Apr 2.

PMID:
23553436
47.

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA.

Blood. 2013 Apr 4;121(14):2689-703. doi: 10.1182/blood-2012-04-425033. Epub 2013 Feb 7.

48.

Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors.

Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S.

CMAJ. 2013 Mar 5;185(4):E201-11. doi: 10.1503/cmaj.120744. Epub 2013 Jan 28. Review.

49.

Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.

Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J.

Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7.

PMID:
23294528
50.

Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.

Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, Goldwein J, Mehta M, Packer RJ, Tarbell N, Fitz C, Vezina G, Hilden J, Pollack IF.

J Clin Oncol. 2012 Jul 20;30(21):2648-53. doi: 10.1200/JCO.2011.40.2792. Epub 2012 Jun 4.

Supplemental Content

Loading ...
Support Center